DaVita Inc.

DB:TRL Stock Report

Market Cap: €13.0b

DaVita Valuation

Is TRL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TRL (€159.7) is trading below our estimate of fair value (€397.17)

Significantly Below Fair Value: TRL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRL?

Key metric: As TRL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TRL. This is calculated by dividing TRL's market cap by their current earnings.
What is TRL's PE Ratio?
PE Ratio16.4x
EarningsUS$827.68m
Market CapUS$13.57b

Price to Earnings Ratio vs Peers

How does TRL's PE Ratio compare to its peers?

The above table shows the PE ratio for TRL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.4x
FME Fresenius Medical Care
19.1x19.3%€12.6b
SYAB SYNLAB
28.1x-11.4%€2.5b
AFX Carl Zeiss Meditec
25.4x16.3%€5.2b
SHL Siemens Healthineers
29.1x14.2%€56.5b
TRL DaVita
16.4x4.3%€13.6b

Price-To-Earnings vs Peers: TRL is good value based on its Price-To-Earnings Ratio (16.4x) compared to the peer average (25.4x).

Price to Earnings Ratio vs Industry

How does TRL's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
TRL 16.4xIndustry Avg. 18.8xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TRL is good value based on its Price-To-Earnings Ratio (16.4x) compared to the European Healthcare industry average (18.7x).

Price to Earnings Ratio vs Fair Ratio

What is TRL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.4x
Fair PE Ratio22.6x

Price-To-Earnings vs Fair Ratio: TRL is good value based on its Price-To-Earnings Ratio (16.4x) compared to the estimated Fair Price-To-Earnings Ratio (22.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TRL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€159.70
€146.17
-8.5%
10.1%€173.28€124.83n/a9
Nov ’25€128.00
€144.77
+13.1%
10.4%€171.01€123.20n/a9
Oct ’25€146.40
€138.35
-5.5%
8.0%€158.11€121.07n/a8
Sep ’25€137.85
€133.42
-3.2%
10.2%€157.29€111.00n/a8
Aug ’25€125.70
€132.47
+5.4%
10.0%€155.94€112.57n/a8
Jul ’25€128.40
€130.67
+1.8%
10.0%€155.31€112.12n/a8
Jun ’25€137.50
€130.67
-5.0%
10.0%€155.31€112.12n/a8
May ’25€128.45
€119.41
-7.0%
5.9%€132.59€109.55n/a9
Apr ’25€125.70
€119.41
-5.0%
5.9%€132.59€109.55n/a9
Mar ’25€117.10
€118.40
+1.1%
6.7%€133.69€110.46n/a8
Feb ’25€100.90
€99.17
-1.7%
8.6%€109.81€82.36n/a8
Jan ’25€93.94
€96.66
+2.9%
7.2%€105.49€82.56n/a8
Dec ’24€93.58
€95.69
+2.3%
6.5%€103.60€82.51n/a8
Nov ’24€74.00
€104.47
+41.2%
11.2%€133.79€94.22€128.008
Oct ’24€90.72
€107.70
+18.7%
10.4%€134.45€94.68€146.408
Sep ’24€94.16
€104.78
+11.3%
10.1%€130.23€91.71€137.858
Aug ’24€92.28
€93.42
+1.2%
6.5%€102.44€85.52€125.708
Jul ’24€90.46
€95.55
+5.6%
5.6%€104.83€89.06€128.408
Jun ’24€87.32
€91.93
+5.3%
7.8%€103.89€78.06€137.508
May ’24€79.46
€82.26
+3.5%
7.8%€98.31€77.28€128.458
Apr ’24€72.54
€82.24
+13.4%
10.0%€100.66€68.97€125.708
Mar ’24€77.28
€83.81
+8.4%
11.4%€101.89€69.81€117.106
Feb ’24€75.22
€78.24
+4.0%
14.7%€102.63€68.42€100.906
Jan ’24€70.40
€78.04
+10.8%
15.3%€104.26€69.51€93.946
Dec ’23€70.15
€78.04
+11.2%
15.3%€104.26€69.51€93.586
Nov ’23€73.97
€84.59
+14.4%
14.6%€109.32€72.88€74.007

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%